The National Agency for Food and Drug Administration and Control has refuted social media claims that it has banned Camosunate, an antimalarial drug, in Nigeria.
The agency clarified its position in a press release dated November 21, 2026, and signed by its Director-General, Professor Mojisola Adeyeye.
NAFDAC maintained that it had never banned Camosunate or other medicines containing the artesunate-amodiaquine combination, although it acknowledged that some of the symptoms mentioned in the viral reports could be linked to known side effects of the drug.
The agency explained that Camosunate contains artesunate and amodiaquine, two active pharmaceutical ingredients used in malaria treatment, stressing that neither the drug nor other medicines containing the combination had been prohibited in Nigeria.
“The National Agency for Food and Drug Administration and Control (NAFDAC) is refuting claims circulating on social media that Camosunate, an antimalarial medicine containing artesunate and amodiaquine, has been banned in Nigeria. The Agency clarifies that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination,” the statement read in part.
The agency acknowledged that some symptoms cited in the circulating claims, including nausea, vomiting, diarrhoea, abdominal pain, headaches, dizziness, drowsiness and loss of appetite, are recognised side effects associated with Camosunate.
NAFDAC, however, urged the public to report suspected adverse reactions for proper investigation and assessment, stressing that such reports should not be interpreted as evidence that the drug has been banned or is unsafe for use.
NAFDAC advised members of the public and healthcare professionals to report suspected adverse drug reactions through its Med Safety App, available on Android and iOS devices, or at the nearest NAFDAC office.
The agency also urged Nigerians to stop circulating claims that Camosunate had been banned, describing the reports as false. It encouraged those who had already shared the information to disseminate its clarification through the same channels to help counter the misinformation.
The controversy followed a reported declaration by the Chairman of the Edo State Consumer Protection Committee, Osaro Iyamu, that Camosunate was a banned medicinal product in Nigeria.